Results of the 2018 Annual Meeting of Shareholders
* Passing of the resolutions within the competence of the Ordinary General
* Appointments of Eric Rowinsky and Dimitri Batsis to the Board of Directors
Second convening notice to the Extraordinary General Meeting on June 4th, 2018
Paris (France), May 16th, 2018, 8pm - BIOPHYTIS (Euronext Growth Paris: ALBPS),
a biotechnology company specializing in the development of drug candidates for
the treatment of degenerative age- related diseases, announces the approval of
all resolutions submitted to shareholders during the Ordinary General Meeting,
particularly those related to the appointments of Mr. Eric Rowinsky and Mr.
Dimitri Batsis as independent administrators to Biophytis' Board of Directors.
The Extraordinary General Meeting could not validly deliberate owing to lack of
quorum. Consequently, shareholders are being convened again on June 4th, 2018,
to rule on the same agenda.
Biophytis' shareholders met for the combined General Meeting on June 16, 2018.
The shareholders present or represented taking part in the vote altogether
owned 2,784,761 shares, reaching a quorum of 20.77%, and 4,200,473 voting
Voting Results of the Ordinary General Meeting
The shareholders approved by a very large majority all the resolutions within
the competence of the Ordinary General Meeting, including those ratifying the
renewal of mandates of Ms. Nadine Coulm, Mr. Jean-Gérard Galvez and Mr.
Stanislas Veillet, as well as the appointments of Mr. Eric Rowinsky and Mr.
Dimitri Batsis as independent administrators of Biophytis for a duration of 3
The ensuing Board meeting that was held at 2:30 pm, following the General
Meeting, has reappointed Stanislas Veillet as Chairman.
Eric Rowinsky is a medical doctor focused on the comprehensive development and
registration strategies of cancer therapeutics of all types. He also has
extensive teaching experience, notably at the Johns Hopkins University School
of Medicine. Since 2015, he has served as an Executive Director and President
at Rgenix, a life sciences company focused on discovering new cancer targets
using a novel microRNA platform licensed, as well as the Chief Scientific
Director of Clearpath Development. He also sits on the Board of Directors or
the Scientific Board of several private or listed companies such as Biogen Inc
or Fortress Biotech. He is also Editor-in-Chief of Investigational New Drug and
has published around 315 manuscripts in both the nonclinical and clinical
Dimitri Batsis is a successful entrepreneur who created in 1987 the web agency
Zeni-Corporation, listed on the Paris Stock Exchange and then bought up by
Keyrus group in 2007. He then founded Drone Volt, a company specializing in the
design, Meeting and commercialization of civilian drones, which has been
recording a triple digit growth since 2012. The company, of which he is a
shareholder, is listed on Euronext Growth and settled in 30 countries. Dimitri
Batsis is today a business angel and Chairman of Dimitri Batsis Investments.
Other key resolutions approved were:
- The social and consolidated accounts for fiscal year 2017
- The allocation of profit for the fiscal year ended December 31, 2017
Full results of votes on resolutions will be available on the Company's website
as of May 17th, 2018, in the " Investors / Regulated information " section.
Convening of a new Extraordinary General Meeting on June 4, 2018, with the same
In the absence of a sufficient quorum, resolutions within the competence of the
Extraordinary General Meeting could not be put to the vote.
The Board of Directors decided accordingly that a new Extraordinary General
Meeting will be held on a second convening on June 4, 2018 at 9.30am at the
following address Sorbonne Université, 4 place Jussieu, 75005 Paris, to rule
on the same agenda.
Shareholders who would have already casted their votes with the postal voting
form or by proxy for the Combined Shareholders' Meeting of May 16th, 2018, do
not need to return a new voting form, subject to the conservation of their
Shareholders who attended the Combined General Meeting on May 16, 2018 and who
could not attend the next Extraordinary General Shareholders' Meeting on June
4th, 2018 are also invited to send their forms and shareholder certificates
within the aforementioned period.
Shareholders who would have not voted by post or proxy as part of the first
convening notice are invited to send their forms and shareholder certificates
by May 31st, 2018 at the latest.
By post : CACEIS Corporate Trust, Service Assemblées Générales Centralisées
- 14, rue Rouget de L'Isle - 92862 ISSY-LES-MOULINEAUX Cedex 9, or via email:
Biophytis SA (www.biophytis.com), founded in 2006, develops drug candidates
targeting diseases of aging. Using its technology and know-how, Biophytis has
begun clinical development of innovative therapeutics to restore the muscular
and visual functions in diseases with significant unmet medical needs.
Specifically, the company is advancing two lead products into mid-stage
clinical testing this year: Sarconeos (BIO101) to treat sarcopenic obesity and
Macuneos (BIO201) to treat dry age-related macular degeneration (AMD).
The business model of BIOPHYTIS is to ensure the conduct of the project until
clinical activity in the patient is proven, then to license the technologies in
order to continue the development in partnership with a pharmaceutical
Based on the Sorbonne Université campus, Biophytis collaborates with expert
scientists from several Sorbonne Université institutes such as the Paris Seine
Biology Institute, the Institute of Myology, and the Vision Institute.
BIOPHYTIS is listed on the Euronext Growth market of Euronext Paris (ALBPS;
For more information: http://www.biophytis.com
Follow us on Twitter @biophytis
BIOPHYTIS is eligible for the SMEs scheme
This press release contains certain forward-looking statements. Although the
Company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the Company's
actual results, financial condition, performance or achievements to differ from
those contained in the forward looking statements, please refer to the Risk
Factors ("Facteurs de Risque") section of the Listing Prospectus upon the
admission of Company's shares for trading on the regulated market Euronext
Growth of Euronext Paris filed with the AMF, which is available on the AMF
website (www.amf- france.org) or on BIOPHYTIS' website (www.biophytis.com).
This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to shares in
BIOPHYTIS in any country. Items in this press release may contain
forward-looking statements involving risks and uncertainties. The Company's
actual results could differ substantially from those anticipated in these
statements owing to various risk factors which are described in the Company's
prospectus. This press release has been prepared in both French and English. In
the event of any differences between the two texts, the French language version